Table 1.
Participant Demographic and Health Information (n=24)
| n (%) | Mean (SD) Range |
|
|---|---|---|
| Age (years) | 64.9 (8.0) | |
| 40–80 | ||
| Sex | ||
| Female | 6 (25) | |
| Male | 18 (75) | |
| Highest level of education completed | ||
| Some elementary | 2 (8.3) | |
| Some secondary | 3 (12.5) | |
| Completed secondary | 2 (8.3) | |
| Some college/university | 4 (16.7) | |
| Completed college/university | 10 (41.7) | |
| Graduate degree | 3 (12.5) | |
| Living arrangement | ||
| Lives with others | 22 (91.7) | |
| Lives alone | 2 (8.3) | |
| Employment status | ||
| Retired | 18 (75) | |
| Working part time | 1 (4.2) | |
| Working full time | 5 (20.8) | |
| Years since diagnosis | 4.5 (4.3) | |
| 0–20 | ||
| H & Y | ||
| Stage 1 | 13 (54.2) | |
| Stage 2 | 6 (25.0) | |
| Stage 3 | 5 (20.8) | |
| MMSE score | 27.4 (2.5) | |
| 26–30** | ||
| BDI score | 9.0 (5.6) | |
| 0–19 | ||
| PD medications* | ||
| L-dopa | 5 (20.8) | |
| Sinemet | 3 (12.5) | |
| Amantadine | 12 (50) | |
| Mirapex | 7 (29.2) | |
| Requip | 3 (12.5) | |
| Number of falls in past 2 weeks | 0.25 (1.0) | |
| 0– 5 | ||
| Number of near-falls in past 2 weeks | 0.54 (2.0) | |
| 0–10 |
*
Medication percentages do not total 100% because 44.4% of subjects taking two or more PD medications.
**
Scores reflect age- and education-adjusted MMSE scores.
H & Y=Hoehn & Yahr stages of disease progression; MMSE=Mini–Mental State Exam scores; BDI=Beck Depression Index; PD=Parkinson disease